{"entity":{"id":"nct05362409","kind":"trial","name":"Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma","aka":[],"tldr":"A phase 1 trial of PoMA sonodynamic therapy run by Alpheus Medical, Inc., completed.","summary":"Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma is a phase 1 interventional study registered as NCT05362409 by Alpheus Medical, Inc., with 22 participants enrolled, started 2022-06-29, primary completion reached 2024-12-03. Conditions recorded: High Grade Glioma. Interventions recorded: 5 Aminolevulinic Acid, CV01-delivered ultrasound.","status":"completed","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT05362409","url":"https://clinicaltrials.gov/study/NCT05362409"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["poma-sonodynamic-therapy"],"companies":["alpheus-medical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05362409","phase":"1","setting":"A Phase 1 Multi-center Clinical Trial Evaluating the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy(SDT) in Patients With Recurrent High Grade Glioma (HGG)","sponsor":"Alpheus Medical, Inc.","enrolled":22,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05362409/","neighbours":{"drug":[{"id":"poma-sonodynamic-therapy","kind":"drug","name":"PoMA sonodynamic therapy","route":"/drugs/poma-sonodynamic-therapy/"}],"company":[{"id":"alpheus-medical","kind":"company","name":"Alpheus Medical","route":"/companies/alpheus-medical/"}]}}